Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison

Molecular Pharmacology

Volumn 54, Issue 1, 1998, Pages 50-58

  Kohlhagen, Glenda ^a   Paull, Kenneth D ^a   Cushman, Mark ^b   Nagafuji, Pamela ^b   Pommier, Yves ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PURDUE UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIHYDRO 5,11 DIKETO 2,3 DIMETHOXY 6 METHYL 8,9 METHYLENEDIOXY 11H INDENO[1,2 C]ISOQUINOLINE; CAMPTOTHECIN; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; PROTEIN; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DNA DAMAGE; DNA STRAND BREAKAGE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL;

EID: 0031815336     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.54.1.50     Document Type: Article

References (41)

1. Alverez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, and Fojo T (1995) Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein expression in cell lines of the NCI Anticancer Screen. J Clin Invest 95:2205-2214.
2. Bertrand R and Pommier Y (1995) Assessment of DNA damage in mammalian cells by DNA filtration methods, in Cell Growth and Apoptosis: A Practical Approach (G Studzinski, ed) pp 96-117, IRL Press, Oxford University Press, Oxford.
3. Boyd MR and Paull KD (1995) Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Develop Res 34:91-109.
4. Champoux J (1990) Mechanistic aspects of type-I topoisomerases, in DNA Topology and Its Biological Effects (Wang JC and Cozarelli NR, eds) pp 217-242, Cold Spring Harbor Laboratory, Cold Spring Harbor.
5. Chen AY and Liu LF (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 94:194-218.
6. Chen AY, Yu C, Bodley A, Peng LF, and Liu LF (1993) A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res 53:1332-1337.
7. Covey JM, Jaxel C, Kohn KW, and Pommier Y (1989) Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 49:5016-5022.
8. Cushman M and Cheng L (1978) Stereoselective oxidation by thionyl chloride leading to the indeno[1,2-c]isoquinoline system. J Org Chem 43:3781-3783.
9. Fang S-D, Wang L-K, and Hecht SM (1993) Inhibitors of DNA topoisomerase I isolated from the roots of Zanthoxylum nitidum. J Org Chem 58:5025-5027.
10. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, and Pommier Y (1995) Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell resistant to camptothecin. Cancer Res 55:1339-1346.
11. Fujimori A, Hoki Y, Popescu N, and Pommier Y (1996) Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. Oncol Res 8:295-301
12. Gatto B, Sanders MM, Yu C, Wu HY, Makhey D, LaVoie EJ, and Liu LF (1996) Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res 56:2795-2800.
13. Gupta M, Abdel-Megeed M, Hoki Y, Kohlhagen G, Paull K, and Pommier Y (1995a) Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517. Mol Pharmacol 48:658-665.
14. Gupta M, Fujimori A, and Pommier Y (1995b) Eukaryotic DNA topoisomerases I. Biochem Biophys Acta 1262:1-14.
15. Hsiang YH, Hertzberg R, Hecht S, and Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878.
16. Jaxel C, Kohn KW, Wani MC, Wall ME, and Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465-1469.
17. Kim JS, Gatto B, Yu C, Liu A, Liu LF, and LaVoie EJ (1996) Substituted 2,5′-Bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity. J Med Chem 39:992-998.
18. Larsen AK, Grondard L, Couprie J, Desoizé B, Comof L, Jardillier J-C, and Riou J-F (1993) The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol 19:1403-1412.
19. Lee J-S, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, and Bates SE (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute Drug Screen. Mol Pharmacol 46:627-638.
20. Leteurtre F, Fujimori A, Tanizawa A, Chhabra A, Mazumder A, Kohlhagen G, Nakano H, and Pommier Y (1994) Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J Biol Chem 269:28702-28707.
21. Nitiss JL, Pourquier P, and Pommier Y (1997) Aclarubicin stabilizes topoisomerase I covalent complexes. Cancer Res 57:4564-4569.
22. Nitiss J and Wang JC (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85:7501-7505.
23. Paull KD, Hamel E, and Malspeis L (1995) Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute, in Cancer Chemotherapeutic Agents (Foye WO, ed) pp 8-45, American Chemical Society, Washington, DC.
24. Paull KD, Lin CM, Malspeis L, and Hamel E (1992) Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 52:3892-3900.
25. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, and Boyd M (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of a mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088-1092.
26. Poddevin B, Riou J-F, Lavelle F, and Pommier Y (1993) Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol 44:767-774.
27. Pommier Y (1996) Eukaryotic DNA topoisomerase I: genome gate keeper and its intruders, camptothecins. Semin Oncol 23:1-10.
28. Pommier Y (1997) DNA topoisomerase II inhibitors, in Cancer Therapeutics: Experimental and Clinical Agents (Teicher BA, ed) pp 153-174, Humana, Totowa, NJ.
29. Pommier Y (1998) Diversity of DNA topoisomerases I and inhibitors. Biochimie, in press.
30. Pommier Y, Covey JM, Kerrigan D, Markovits J, and Pham R (1987) DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucl Acids Res 15:6713-6731.
31. Pommier Y, Kohlhagen G, Kohn F, Leteurtre F, Wani MC, and Wall ME (1995) Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci USA 92:8861-8865.
32. Riou J-F, Helissey P, Grondard L, and Giorgi-Renault S (1991) Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives. Mol Pharmacol 40:699-706.
33. Solary E, Leteurtre F, Paull KD, Scudiero D, Hamel E, and Pommier Y (1993) Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochem Pharmacol 45:2449-2456.
34. Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F, and Pommier Y (1995) Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 43:7200-7206.
35. Trask DK and Muller MT (1988) Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA 85:1417-1421.
36. Valenti M, Nieves-Neira W, Kohlhagen G, Kohn KW, Wall ME, Wani MC, and Pommier Y (1997) Novel 7-alkyl methylenedioxycamptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Mol Pharmacol 52:82-87.
37. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635-692.
38. Wassermann K, Markovits J, Jaxel C, Capranico G, Kohn KW, and Pommier Y (1990) Effects of morpholinyl doxorubicins, doxorubicin and actinomycin D on mammalian DNA topoisomerases I and II. Mol Pharmacot 38:38-45.
39. Yamashita Y, Fujii N, Murakata C, Ashizawa T, Okabe M, and Nakano H (1992) Induction of mammalian DNA topoisomerase I-mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 31:12069-12075.
40. Yamashita Y, Kawada S-Z, Fujii N, and Nakano H (1991) Induction of mammalian topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry 30:5838-5845.
41. Yoshinari T, Matsumoto M, Arakawa H, Okada H, Noguchi K, Suda H, Okura A, and Nishimura S (1995) Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H- indolo[2, 3-a] pyrrolo[3,4-c] carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res 55:1310-1315.